Immune Checkpoint Inhibitors Programmed Cell Death-1/Programmed Cell Death-Ligand1 (PD-1/PD-L1) for Cancer Therapy
Monoclonal antibodies that inhibit “immune checkpoint” through programmed cell death-1 and its ligand (PD-1/PD-L1) blockage have proven remarkable therapeutic action toward a range of cancer types. Hence, immunotherapy, binding the immune system to act against malignant tumors, has generated encoura...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/84476 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Immune Checkpoint Inhibitors Programmed Cell Death-1/Programmed Cell Death-Ligand1 (PD-1/PD-L1) for Cancer Therapy
- The Program Cell Death (Apoptosis) and the Therapy of Cancer
- The Science of PD-1/PD-L1 Pathway in Gliomas: Far beyond the Obvious
- Sensitivity and Resistance to PD-1/PD-L1 Blockade: A Comprehensive Molecular Overview
- Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy
- Programmed Cell Death in T Cell Development
- Erythrocyte: Programmed Cell Death